Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma
Conditions
Brief summary
This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Detailed description
PRIMARY OBJECTIVES: I. Determine the effect of pazopanib hydrochloride on the proportion of patients with malignant pleural mesothelioma who are progression-free at 6 months based on the RECIST criteria. II. Determine the clinical toxicities of this drug in this patient population. SECONDARY OBJECTIVES: I. Determine the objective tumor response status in these patients as measured by the RECIST criteria or the modified RECIST criteria. II. Determine the response rate in patients treated with this drug. III. Determine the effect of this drug on overall survival and time to progression in these patients. IV. Assess predictive markers of activity of this drug in these patients. V. Assess serologic markers of target inhibition by this drug in these patients. VI. Determine the clinical toxicities of this drug in this patient population. OUTLINE: This is a multicenter study. Patients receive oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Blood is collected at baseline and prior to each course of therapy and analyzed for markers of angiogenesis. After completion of study therapy, patients are followed every 3 months.
Interventions
OTHERlaboratory biomarker analysis
Correlative study
DRUGpazopanib hydrochloride
Given orally
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed malignant pleural mesothelioma: * Measurable disease * No progressive disease inside or outside of any prior radiation field * No symptomatic, untreated, or uncontrolled CNS metastases * Patients with CNS metastases treated with whole brain radiation (WBRT) may be enrolled after completion of WBRT * Patients may begin study therapy as early as the next day after completion of WBRT * ECOG performance status 0-2 * Life expectancy \>= 12 weeks * ANC \>=1,500/mm\^3 * Platelet count \>= 100,000/mm\^3 * WBC \>= 3,000/mm\^3 * Bilirubin =\< 1.5 times upper limit of normal (ULN) * AST and ALT =\< 2.5 times ULN * Alkaline phosphatase =\< 2.5 times ULN * Creatinine =\< 1.5 times ULN or creatinine clearance \>= 50 mL/min * Proteinuria =\< 1+ on 2 consecutive dipsticks taken \>= 1 week apart * No condition that impairs ability to swallow and retain study drug tablets including, but not limited to, any of the following: * Gastrointestinal tract disease resulting in an inability to take oral medication * Requirement for IV alimentation * Prior surgical procedures affecting absorption * Active peptic ulcer disease * No other primary malignancy except for carcinoma in situ of the cervix or nonmelanomatous skin cancer, unless that prior malignancy was diagnosed and definitively treated ≥ 5 years ago with no subsequent evidence of recurrence * Patients with a history of low-grade (Gleason score =\< 6) localized prostate cancer are eligible even if diagnosed within the past 5 years * No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or other agents used in the study * None of the following concurrent severe and/or uncontrolled medical conditions: * Serious or nonhealing wound, ulcer, or bone fracture * Abdominal fistula, diverticulosis, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days * Poorly controlled diabetes * Interstitial pneumonia * Extensive and symptomatic interstitial fibrosis of the lung * No cardiovascular illness or complication, including any of the following: * Any history of cerebrovascular accident within the past 6 months * History of myocardial infarction (prior electrocardiographic evidence of myocardial injury) * History of cardiac arrhythmia (prior electrocardiographic evidence of abnormal heart rhythm) * Admission for unstable angina * Cardiac angioplasty or stenting within the past 12 months * NYHA class III-IV heart failure * Asymptomatic NYHA class II heart failure allowed * QTc prolongation (defined as a QTc interval ≥ 500 msecs) or other significant electrocardiogram abnormalities * Venous thrombosis within the past 12 weeks * No ancillary therapy considered investigational within the past 4 weeks * No symptomatic, untreated, or uncontrolled seizure disorder * No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit study compliance * No significant traumatic injury within the past 4 weeks * No more than 1 prior systemic therapy for malignant pleural mesothelioma * No major surgery (i.e., laparotomy) or open biopsy within the past 4 weeks * Insertion of a vascular access device is not considered major or minor surgery * No minor surgery within the past 2 weeks * Insertion of a vascular access device is not considered major or minor surgery * Prior palliative radiotherapy allowed * No prior palliative radiotherapy to the chest except for a maximum of 3 fractions of radiotherapy for superior vena cava syndrome * No concurrent therapeutic warfarin * Low molecular-weight heparin or prophylactic low-dose warfarin allowed * No other concurrent chemotherapy, immunotherapy, hormonal therapy, or radiotherapy * No concurrent medications that act through the CYP450 system * No concurrent combination antiretroviral therapy for HIV-positive patients * PT/INR/PTT =\< 1.2 times ULN * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective nonhormonal contraception * No uncontrolled infection * No uncontrolled blood pressure (BP) (defined as systolic BP \> 140 mm Hg and/or diastolic BP \> 90 mm Hg in spite of adequate anti-hypertensive therapy) * No other severe underlying disease that, in the judgment of the investigator, would limit study compliance
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST) | 6 months | The proportion of patients who are progression-free at 6 months is calculated by dividing the number of evaluable participants who are progression-free at 6 months based on the Response Evaluation Criteria for Solid Tumors (RECIST) by the total number of evaluable participants. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | From study enrollment to time of death from any cause or censored at last follow-up, up to 3 years | — |
| Progression-free Survival Assessed by RECIST | From study enrollment to the first date of disease progression or death as a result of any cause, whichever occurs first, up to 3 years | — |
| Determine the Clinical Toxicities of This Drug in This Participant Population. | Participants will be evaluated every cycle during treatment | The number of participants with a reported Grade 3, Grade 4, and Grade 5 toxicity, regardless of attribution, will be tabulated. |
| Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST. | From study enrollment to the first date of disease progression | Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline LD. |
| Overall Response Rate | Participants will be evaluated every cycle during treatment, up to 2 years | To evaluate the confirmed response rate of pazopanib in patients with MPM based on the RECIST criteria for MPM. Responses are confirmed by repeat assessments that are be performed no less than 4 weeks after the criteria for response are first met. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. |
Countries
United States
Participant flow
Recruitment details
Thirty-four participants were accrued between May 2007 and October 2008.
Pre-assignment details
All 34 participants were evaluable for the primary endpoint.
Participants by arm
| Arm | Count |
|---|---|
| Arm I Patients receive oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. | 34 |
| Total | 34 |
Baseline characteristics
| Characteristic | Arm I |
|---|---|
| Age, Continuous | 73 years |
| Region of Enrollment United States | 34 participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 28 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 34 / 34 |
| serious Total, serious adverse events | 13 / 34 |
Outcome results
Primary
Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST)
The proportion of patients who are progression-free at 6 months is calculated by dividing the number of evaluable participants who are progression-free at 6 months based on the Response Evaluation Criteria for Solid Tumors (RECIST) by the total number of evaluable participants.
Time frame: 6 months
Population: All 34 participants were analyzed for this endpoint.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I | Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST) | 47.8 percentage of participants |
Secondary
Determine the Clinical Toxicities of This Drug in This Participant Population.
The number of participants with a reported Grade 3, Grade 4, and Grade 5 toxicity, regardless of attribution, will be tabulated.
Time frame: Participants will be evaluated every cycle during treatment
Population: All 34 participants were evaluable for adverse events.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm I | Determine the Clinical Toxicities of This Drug in This Participant Population. | Grade 3 or Higher | 23 participants |
| Arm I | Determine the Clinical Toxicities of This Drug in This Participant Population. | Grade 4 or Higher | 5 participants |
| Arm I | Determine the Clinical Toxicities of This Drug in This Participant Population. | Grade 5 | 3 participants |
Secondary
Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST.
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline LD.
Time frame: From study enrollment to the first date of disease progression
Population: All 34 participants were evaluable for this endpoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm I | Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST. | Partial Response (PR) | 5 participants |
| Arm I | Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST. | Complete Response (CR) | 0 participants |
Secondary
Overall Response Rate
To evaluate the confirmed response rate of pazopanib in patients with MPM based on the RECIST criteria for MPM. Responses are confirmed by repeat assessments that are be performed no less than 4 weeks after the criteria for response are first met. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
Time frame: Participants will be evaluated every cycle during treatment, up to 2 years
Population: All 34 participants were evaluable for this endpoint.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I | Overall Response Rate | 5.9 percentage of patients |
Secondary
Overall Survival
Time frame: From study enrollment to time of death from any cause or censored at last follow-up, up to 3 years
Population: All 34 participants were evaluable for this endpoint.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I | Overall Survival | 11.5 months |
Secondary
Progression-free Survival Assessed by RECIST
Time frame: From study enrollment to the first date of disease progression or death as a result of any cause, whichever occurs first, up to 3 years
Population: All 34 participants were analyzed for this endpoint.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I | Progression-free Survival Assessed by RECIST | 4.2 months |